Characterization of etoricoxib, a novel, selective COX-2 inhibitor. - Wikidata - awgldk - TriplyDB

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

http://www.wikidata.org/entity/Q44484802

about

Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study.Etoricoxib--preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy--design and protocols Etoricoxib and the treatment of ankylosing spondylitis.Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.Clinical pharmacology of etoricoxib.Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.Etoricoxib for arthritis and pain management Synthesis of Diarylpyrazoles Containing a Phenylsulphone or Carbonitrile Moiety and their Chalcones as Possible Anti-Inflammatory Agents.Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy Preoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain relief Evaluation of a single preoperative dose of etoricoxib for postoperative pain relief in therapeutic knee arthroscopy: a randomized trial.Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib Using pharmacokinetic principles to optimize pain therapy.Combination of etoricoxib and low-pressure pneumoperitoneum versus standard treatment for the management of pain after laparoscopic cholecystectomy: a randomized controlled trial.NSAIDs and opioids in management of fragility fractures.The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.Efficacy of celecoxib in the treatment of joint pain caused by advanced haemophilic arthropathy in adult patients with haemophilia A.Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib.Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib.Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.Effects of preemptive analgesia in laparoscopic cholecystectomy: a double-blind randomized controlled trial.Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion.Analgesics and Antipyretics

P2860

Q30629677-4131FF8C-84EE-4915-9AFA-51C9255999A3 Q33596397-6EA9D7BC-0A7C-4831-A8CF-F841831C8325 Q33934086-EDA29473-98DB-43F9-84B5-BEF7CAFA8777 Q34466689-2DDE8EC9-E654-4FCC-85F8-9D8E5F12A029 Q34556831-022933A0-EB45-4727-A689-9A0F5EAE3BD9 Q34570225-F309CDF4-F4E7-45F1-B1B3-D5E9E0667AAE Q34610283-465A6E9E-38B5-40E4-B25F-66B2476B747C Q35166773-C28FB3F8-F2F1-4651-86D6-FEFBDE3FEFAB Q35185323-EC0DEABF-EFD4-48C9-BB24-F54C3B51B2CF Q35849418-A54747C1-4967-427E-82BE-68874BA4B8A1 Q36220369-112A7E20-E0F5-4B07-A2DB-D0E69886692C Q36563754-FCF8E13A-1957-46A6-A445-3C33E8E90541 Q37175779-8D6F0A23-EF6C-4681-91E7-D5F2C440552C Q37785746-9540D6B5-6F65-4E54-9DFD-3A56C7C63B0B Q40514029-58D8D877-8C76-4383-86A0-BAB9AC51727D Q43657363-9243E17F-2CA2-491E-B8CC-2526BFBD697F Q45040968-17BDFF4B-E710-411F-94C1-B9C6E2099AAF Q45863072-D2EDD992-880F-44D9-9210-B9D31F9F3A30 Q46152222-5095AB6C-CFFB-4D40-88D2-3B02EFCFB455 Q46382423-7F292613-EE55-4C60-A005-C2B586EBF048 Q46628463-5B97C1EF-3BF4-41C8-834E-89697CB686EC Q47372560-7A60A726-D8F4-4238-BB85-B84933CA10A1 Q48347246-23739522-4D70-4F11-9AC8-BCA414C38D87 Q53602109-F64C8CAC-F946-4EBE-A942-911D2F602E83 Q56113559-A26CF673-71EE-4E96-BF9B-DF4B1B1BC39F

P2860

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

http://www.wikidata.org/entity/Q44484802

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

@en

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

@nl

type

label

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

@en

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

@nl

prefLabel

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

@en

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

@nl

P1433

Q44484802-8EA928AE-1392-4BC4-8811-411C1AC2DEF5

P1476

Q44484802-2ACE7354-4B49-444C-89C0-A5B31DE10A0A

P2093

Q44484802-187238A0-8913-4568-ABD4-679D7E13E22A

Q44484802-41C649DF-CE5B-4E62-9C6E-5CF30106A320

Q44484802-488CE346-C99F-4672-801C-DE2BC9063E06

Q44484802-49BA77FF-52FA-4F41-AA71-9CB52306617C

Q44484802-50177CCF-A37A-4A73-9103-A1BDEB6D59CD

Q44484802-5CDC7159-737D-4D51-BBAE-A0FA0F0CEA55

Q44484802-727637ED-9977-4C40-A8CD-FD7D7108620C

Q44484802-7C00910B-DFFE-4BCB-B91F-31A9A60BD54D

Q44484802-820BE3DD-E64A-47F0-A34D-F5B233313991

Q44484802-8280D23C-8E48-4DDA-83AD-A89069845B32

P2860

Q44484802-017F89E9-1786-4BAC-8E30-3BE5A6234A19

Q44484802-087FEEE2-8925-4AB5-8FC6-8C4ACD0332EA

Q44484802-31C22542-EFF9-40A7-B351-130C96B06AC0

Q44484802-3CE13DF8-6136-4C7B-9C07-8A844CEF5F1F

Q44484802-3DEA33C2-ADED-4679-A6FD-04B4A093EEBE

Q44484802-99F03F58-18E7-4872-992C-2E855AC95E48

Q44484802-B6F830C3-B44F-4148-9864-7AAA9FF41869

Q44484802-C32AEA2C-FE5C-452A-A4D2-0E37690D529A

Q44484802-D2804535-6E93-49F6-906A-300AD16D9526

Q44484802-DACEEA60-27E1-4D5B-A462-8DB88B7420B5

P304

Q44484802-4E6C55D6-8508-4CA7-9D9F-E60264FEC5DE

P31

Q44484802-161D9995-8277-4558-88B3-9C89660BB09B

P356

Q44484802-E44FB790-5DF8-4D93-9F35-E630A507F6B7

P433

Q44484802-AB2388C3-0E9A-47FD-83C4-7ACD5F77BF74

P478

Q44484802-DC5E90EF-5D03-4744-9CFC-A72CBD38C93F

P577

Q44484802-57EAFAFE-902D-497A-8270-3F71BE2EF226

P698

Q44484802-0EC4A220-A8E8-4433-8E68-59CF009E8728

P356

0091270003253703

P1433

The Journal of Clinical Pharmacology

P1476

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

@en

P2093

Aimee Dallob

http://www.w3.org/2001/XMLSchema#string

Barry Gertz

http://www.w3.org/2001/XMLSchema#string

Christopher J Hawkey

http://www.w3.org/2001/XMLSchema#string

Howard Greenberg

http://www.w3.org/2001/XMLSchema#string

John Wagner

http://www.w3.org/2001/XMLSchema#string

Keith Gottesdiener

http://www.w3.org/2001/XMLSchema#string

Lisa DeTora

http://www.w3.org/2001/XMLSchema#string

Nancy Agrawal

http://www.w3.org/2001/XMLSchema#string

Nicholas Wight

http://www.w3.org/2001/XMLSchema#string

Paul De Schepper

http://www.w3.org/2001/XMLSchema#string

P2860

Human cyclooxygenase-2 cDNA

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

Effect of ibuprofen on cardioprotective effect of aspirin

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.

A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin

The coxibs, selective inhibitors of cyclooxygenase-2.

P304

573-585

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270003253703

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12817520

http://www.w3.org/2001/XMLSchema#string